Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma

Preethi Reddy Marri, Lucy S. Hodge, Matthew J. Maurer, Steven C. Ziesmer, Susan L Slager, Thomas Matthew Habermann, Brian K. Link, James R Cerhan, Anne J Novak, Stephen Maxted Ansell

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-a, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse.

Original languageEnglish (US)
Pages (from-to)6812-6819
Number of pages8
JournalClinical Cancer Research
Volume19
Issue number24
DOIs
StatePublished - Dec 15 2013

Fingerprint

Hodgkin Disease
Interleukins
Cytokines
Interleukin-6
Serum
Recurrence
Disease-Free Survival
Survival
Interleukin-2 Receptors
Granulocyte Colony-Stimulating Factor
Interleukin-12
Interleukin-8
Chemokines
Proportional Hazards Models
Epidermal Growth Factor
Thymus Gland
Vascular Endothelial Growth Factor A
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma. / Marri, Preethi Reddy; Hodge, Lucy S.; Maurer, Matthew J.; Ziesmer, Steven C.; Slager, Susan L; Habermann, Thomas Matthew; Link, Brian K.; Cerhan, James R; Novak, Anne J; Ansell, Stephen Maxted.

In: Clinical Cancer Research, Vol. 19, No. 24, 15.12.2013, p. 6812-6819.

Research output: Contribution to journalArticle

Marri, Preethi Reddy ; Hodge, Lucy S. ; Maurer, Matthew J. ; Ziesmer, Steven C. ; Slager, Susan L ; Habermann, Thomas Matthew ; Link, Brian K. ; Cerhan, James R ; Novak, Anne J ; Ansell, Stephen Maxted. / Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 24. pp. 6812-6819.
@article{d2af2171b9e44f71b79b2c08a26a169a,
title = "Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma",
abstract = "Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-a, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse.",
author = "Marri, {Preethi Reddy} and Hodge, {Lucy S.} and Maurer, {Matthew J.} and Ziesmer, {Steven C.} and Slager, {Susan L} and Habermann, {Thomas Matthew} and Link, {Brian K.} and Cerhan, {James R} and Novak, {Anne J} and Ansell, {Stephen Maxted}",
year = "2013",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-13-1879",
language = "English (US)",
volume = "19",
pages = "6812--6819",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Prognostic significance of pretreatment serum cytokines in classical hodgkin lymphoma

AU - Marri, Preethi Reddy

AU - Hodge, Lucy S.

AU - Maurer, Matthew J.

AU - Ziesmer, Steven C.

AU - Slager, Susan L

AU - Habermann, Thomas Matthew

AU - Link, Brian K.

AU - Cerhan, James R

AU - Novak, Anne J

AU - Ansell, Stephen Maxted

PY - 2013/12/15

Y1 - 2013/12/15

N2 - Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-a, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse.

AB - Purpose: Although the International Prognostic Score (IPS) is the gold standard for risk-stratifying patients with classical Hodgkin lymphoma (cHL), these criteria do not accurately predict outcome. As cytokines are critically involved in driving cHL, we tested whether pretreatment serum cytokine levels could provide additional prognostic information. Experimental Design: Thirty cytokines were measured in pretreatment serum from 140 patients with cHL and compared with 50 nonlymphoma controls. Patients were followed for event-free survival (EFS) and overall survival (OS), and Cox proportional hazards regression models were used to assess the association of individual cytokines and the cytokine profiles with outcome via unadjusted and IPS-adjusted HR. Results: Twelve cytokines (EGF, bFGF, G-CSF, HGF, IL-6, IL-8, IL-12, IL-2R, IP-10, MIG, TNF-a, and VEGF) were significantly (P < 0.05) higher in patients with cHL than controls; elevated levels of HGF, IL-6, IL-2R, IP-10, and MIG were all associated with poorer EFS. Only interleukin-2 receptor (IL-2R; P = 0.002) and interleukin (IL)-6 (P < 0.001) were independently prognostic. Patients with increased IL-6 and IL-2R had a significantly higher risk of early relapse and death, a finding that remained significant even after IPS-based risk stratification. Although elevated IL-6 and IL-2R correlated with the IPS, soluble CD30 (sCD30), and thymus and activation-related chemokine (TARC) levels, the two-cytokine model remained independently predictive of prognosis. Conclusions: Elevated pretreatment serum cytokines are associated with increased disease relapse and inferior survival in cHL. Thus, the pretreatment cytokine profile, particularly serum levels of IL-6 and IL-2R, may be used to identify patients with cHL at high risk for early-disease relapse.

UR - http://www.scopus.com/inward/record.url?scp=84890675944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890675944&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-1879

DO - 10.1158/1078-0432.CCR-13-1879

M3 - Article

VL - 19

SP - 6812

EP - 6819

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -